All In MedTech

FDA Clearance Tracker · P110022-S031

Elecsys Anti-HBc IgM and PreciControl Anti-HBc IgM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P110022-S031
Device name
Elecsys Anti-HBc IgM and PreciControl Anti-HBc IgM
Applicant location
Indianapolis, IN
Received
Mar 1, 2024
Decided
Nov 22, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P110022

Device type

Device class
Class II
Regulation
21 CFR 866.3172

Every decision under product code LOM

FDA's approval statement

As written in FDA's record.

Approval for the migration of the Elecsys anti-HBc IgM from the cobas e601 and cobas e411 analyzers to the cobas e402 analyzer, for the update to the biotin interference, and for a room temperature sample stability claim.

Source documents

Other decisions for Roche Diagnostics Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.